paxalisib   Click here for help

GtoPdb Ligand ID: 10097

Synonyms: compound 16 [PMID: 27096040] | GDC-0084 | GDC0084
Compound class: Synthetic organic
Comment: Paxalisib (GDC0084) is a dual PI3K/mTOR inhibitor that was developed by Genentech [1]. It was designed to cross the blood-brain-barrier as a potential oncology drug for the treatment of malignant gliomas.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 117.1
Molecular weight 382.19
XLogP 1.01
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Nc1ncc(cn1)c1nc(N2CCOCC2)c2c(n1)n1CCOC(c1n2)(C)C
Isomeric SMILES Nc1ncc(cn1)c1nc(N2CCOCC2)c2c(n1)n1CCOC(c1n2)(C)C
InChI InChI=1S/C18H22N8O2/c1-18(2)16-22-12-14(25-3-6-27-7-4-25)23-13(11-9-20-17(19)21-10-11)24-15(12)26(16)5-8-28-18/h9-10H,3-8H2,1-2H3,(H2,19,20,21)
InChI Key LGWACEZVCMBSKW-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Paxalisib (GDC0084) has progressed to Phase 2 clinical evaluation in patients with newly-diagnosed glioblastoma multiforme (NCT03522298). The drug developer is Kazia Therapeutics Ltd. Kazia received orphan drug designation (ODD) for paxalisib in glioblastoma in February 2018. In August 2020, the FDA extended the ODD to include the treatment the rare and aggressive childhood brain cancer, diffuse intrinsic pontine glioma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03522298 Safety, Pharmacokinetics and Efficacy of GDC-0084 in Newly-diagnosed Glioblastoma Multiforme Phase 2 Interventional Kazia Therapeutics Limited